IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+12.89%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$317M
AUM Growth
+$317M
(-3.5%)
Cap. Flow
-$31.6M
Cap. Flow
% of AUM
-9.97%
Top 10 Holdings %
Top 10 Hldgs %
36.88%
Holding
89
New
29
Increased
20
Reduced
19
Closed
19
Top Buys
| 1 |
Revvity
RVTY
|
$10M |
| 2 |
Abbott
ABT
|
$6.53M |
| 3 |
Sanofi
SNY
|
$6.27M |
| 4 |
Centene
CNC
|
$5.54M |
| 5 |
eHealth
EHTH
|
$5.53M |
Top Sells
| 1 |
Quest Diagnostics
DGX
|
$13.7M |
| 2 |
LHCG
LHC Group LLC
LHCG
|
$10.6M |
| 3 |
Bristol-Myers Squibb
BMY
|
$9.05M |
| 4 |
Danaher
DHR
|
$7.96M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$7.65M |
Sector Composition
| 1 | Healthcare | 88.17% |
| 2 | Energy | 5.03% |
| 3 | Financials | 1.75% |
| 4 | Consumer Discretionary | 0.61% |
| 5 | Technology | 0.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
AstraZeneca
AZN
$248B
| – | – | -125,000 | Closed | -$6.61M |
|
|
77
Quest Diagnostics
DGX
$20.3B
| – | – | -120,000 | Closed | -$13.7M |
|
|
78
Danaher
DHR
$147B
| – | – | -45,000 | Closed | -$7.96M |
|
79
Exact Sciences
EXAS
$8.98B
| – | – | -55,000 | Closed | -$4.78M |
|
80
Exelixis
EXEL
$10.1B
| – | – | -150,000 | Closed | -$3.56M |
|
81
Incyte
INCY
$16.5B
| – | – | -10,000 | Closed | -$1.04M |
|
82
Inovio Pharmaceuticals
INO
$126M
| – | – | 0 | – | – |
|
83
Eli Lilly
LLY
$657B
| – | – | -35,000 | Closed | -$5.75M |
|
84
Moderna
MRNA
$9.37B
| – | – | 0 | – | – |
|
85
Neurocrine Biosciences
NBIX
$13.8B
| – | – | -20,000 | Closed | -$2.44M |
|
86
Regeneron Pharmaceuticals
REGN
$61.5B
| – | – | -12,000 | Closed | -$7.48M |
|
|
WBA
87
DELISTED
Walgreens Boots Alliance
WBA
| – | – | -40,000 | Closed | -$1.7M |
|
|
SGEN
88
DELISTED
Seagen Inc. Common Stock
SGEN
| – | – | -45,000 | Closed | -$7.65M |
|
|
NUVA
89
DELISTED
NuVasive, Inc.
NUVA
| – | – | -125,000 | Closed | -$6.96M |
|